ALTIMMUNE INC (ALT)
Health Care · Biotechnology · NASDAQ
Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a dual GLP-1/glucagon agonist, to treat serious liver and metabolic disorders.
What ALTIMMUNE INC does
Altimmune is a late-stage clinical biopharmaceutical company focused on developing novel therapies for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and alcohol use disorder (AUD). Its primary product candidate is pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist that is currently undergoing clinical trials. The company does not currently have any commercial products and has not generated revenue from product sales.
Recent developments
In August 2026, the company initiated its global Phase 3 PERFORMA trial for pemvidutide in MASH and reported positive topline Phase 2 data in AUD. The company completed enrollment in its Phase 2 RESTORE trial for ALD and announced plans to relocate its headquarters to Morristown, New Jersey.
From ALTIMMUNE INC's filing of 2026-08-12.
Themes: MASH / fatty liver disease, GLP-1 receptor agonists, alcohol use disorder (AUD) treatment, AI in drug development, metabolic disease
Fundamentals
- Price$2.60 as of 2026-10-08 close
- Market cap$506M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return-33.8% 2025-10-08 close $3.93 → 2026-10-08 close $2.60
- P/En/a negative earnings
- Net margin-214861.0% FY2025, SEC XBRL
- ROE-39.2% FY2025, SEC XBRL
- Debt / equity0.12 as of 2026-09-03
- Revenue growth (YoY)+80.0% as of 2026-09-03
- Beta1.55 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ALT compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALTIMMUNE INC looks technically
ALTIMMUNE INC (ALT) is trading 24.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 127 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-11, breaking below its recent trading range. It is 2.0% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 24.6% below its 200-day average, the long-term trend line — a long-term downtrend | -24.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.07 | $3.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.45 | $3.45 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 3.55. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 127 trading days ago — a "death cross", a bearish long-term signal | 127 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control | 27.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30) | 27.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.55 to $3.42) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 5.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.44 | $6.44 |
|---|---|---|
| From the 52-week high | it is 59.6% below its 52-week high (its highest price of the past year) | -59.6% |
| Above the 52-week low | it is 2.0% above its 52-week low (its lowest price of the past year) | +2.0% |
| Below the 52-week high | it is 59.6% below its highest point of the past year | 59.6% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-11, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-11, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $137.70 (set on 2017-05-26) | $137.70 |
| Given back of the 52-week move | over the past year its closes ranged ($2.59 to $6.18), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.81 to $4.92. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.3% |
| From the all-time high | it is 98.1% below its all-time high | -98.1% |
| Nearest price level | it is trading 1.4% above a support level at $2.56 — a price it turned at twice since 2026-05-01, most recently on 2026-06-11. Since 2024-10-08 it has 1 such level below the current price and 16 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $1.51 (set on 2019-11-19) | $1.51 |
| Above the all-time low | it is 72.2% above its all-time low | +72.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 90% of the past ~6 months) | 90th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1255 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1255 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.51 and $3.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.51 – $3.02 – $3.53 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 6.8 daily ranges below its 200-day average price (24.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.27× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -2.62% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 23.7 percentage points (the stock lost 22.6% while the market gained 1.0%) | -23.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 20.2 percentage points (the stock lost 16.4% while the market gained 3.8%) | -20.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 39.4 percentage points (the stock lost 21.9% while the market gained 17.5%) | -39.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.8 percentage points (the stock lost 33.8% while the market gained 15.0%) | -48.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.0% of the share price, which is taken to mean a barrier that gives way easily. | -14.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.45 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -24.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.07 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -15.4% |
Rising wedge, bearish — broke down · entry $3.05 · 89 sessions in
Price levels it has turned at before
ALT last closed at $2.60 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 16 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.56 | Support | 1.4% below the last close | turned there twice · 2026-05-01 to 2026-06-11 |
| $2.73 | Resistance | 5.2% above the last close | turned there twice · 2026-05-18 to 2026-07-23 |
| $2.85 | Resistance | 9.8% above the last close | turned there twice · 2026-03-30 to 2026-08-13 |
| $3.03 | Resistance | 16.6% above the last close | turned there twice · 2026-06-22 to 2026-09-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.55.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 12 trading days, since 2026-09-23.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.40 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$17.11 range $11.00 – $28.00; median $17.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALT
- Consensus EPS estimate-$0.1367 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.1367, on 2026-09-07, 32-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of significant operating losses and does not have any approved commercial products, creating substantial uncertainty regarding future profitability.","The development of clinical candidates is subject to high failure rates, significant regulatory scrutiny, and unpredictable clinical trial costs and timelines.","The company is highly dependent on the success of its sole clinical lead candidate, pemvidutide; any failure in its development or regulatory approval would have a severe impact on the company."]
What changed in the latest 10-Q
AI-assisted comparison of ALT's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) adds a new 'Headquarters Relocation' subsection under Recent Business Update disclosing a June 16, 2026 announcement to relocate corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey, with a lease and annual rental payments of approximately $0.3 million for a 5-year term.
- Newer filing (2026-08-12) adds a new paragraph under MASH stating that on August 3, 2026, the company announced it has begun enrolling patients in the PERFORMA Phase 3 trial, with a description of the trial as global, Phase 3, randomized, double-blind, placebo-controlled evaluating pemvidutide in MASH patients with moderate to advanced fibrosis.
- Removed:
- Older filing (2026-05-13) contains 'AUD' and 'ALD' subsections under Ongoing Clinical Trials describing the RECLAIM Phase 2 trial for AUD and the RESTORE Phase 2 trial for ALD; these subsections are not present in the newer filing excerpt.
- Older filing (2026-05-13) states the company is in the start-up phase of the PERFORMA Phase 3 trial and was planning to initiate it in the second half of 2026; this plan statement is replaced by the enrollment announcement in the newer filing.
- Reworded:
- Newer filing (2026-08-12) changes the Underwritten Public Offering net proceeds figure from approximately $211.2 million to approximately $211.1 million.
- Newer filing (2026-08-12) changes the phrase 'issuance of combination of common stock' to 'issuance of a combination of common stock' in the Underwritten Public Offering paragraph.
- Newer filing (2026-08-12) changes the cross-reference for warrants from 'See Note 12. Subsequent Events' to 'See Note 7. Stockholders' Equity'.
- Newer filing (2026-08-12) changes 'start up phase of the execution of our PERFORMA Phase 3 trial' language to 'began preparing for our PERFORMA Phase 3 trial', and removes the statement about planning to initiate in the second half of 2026.
- Newer filing (2026-08-12) changes 'MHRA' to 'Medicines and Healthcare products Regulatory Agency (UK)' and 'CRO' to 'Contract Research Organization' in the PERFORMA trial description.
- Newer filing (2026-08-12) changes 'interim analysis after 52 weeks to support with biopsy based-endpoints to support an accelerated approval' to 'interim analysis after 52 weeks with biopsy-based endpoints to support an accelerated approval'.
- Newer filing (2026-08-12) adds quotation marks around 'Enhanced Liver Fibrosis' label reference as "ELF" and "LSM" in the MASH 48-week data discussion; older filing (2026-05-13) did not include quotation marks there (ELF and LSM were without quotes).
- Notes:
- The newer filing MD&A text provided is truncated mid-sentence at 'The 52-week dat'; the comparison cannot assess text after that point.
- The older filing MD&A text is also truncated mid-sentence in the ALD subsection; absence of AUD/ALD sections in the newer filing may reflect truncation of the provided newer excerpt rather than an actual deletion.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-041 buy ($44250) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-041 buy ($44250) · 0 sells — 1 buying insider
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of ALT within a 30-day window between 2026-04-01 and 2026-04-06. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding ALT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 43,489,516
- Reported value $132,208,129
reported quarterly holdings change (2026-03-31 → 2026-06-30): 2 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ALT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ALT had 51,749,756 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ALT had 26.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.38 days to cover at the same settlement.
- Reported short interest (shares) 51,749,756
- Short interest (% of shares outstanding) 26.6%
- Prior settlement (shares) 49,714,773
- Reported change 4.09%
- Days to cover (reported) 15.38
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Madrigal Pharmaceuticals (MDGL)
- Viking Therapeutics (VKTX)
- Akero Therapeutics (AKRO)
- 89bio (ETNB)
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALT vs…
Frequently asked questions
What does ALTIMMUNE INC (ALT) do?
Altimmune is a late-stage clinical biopharmaceutical company focused on developing novel therapies for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and alcohol use disorder (AUD). Its primary product candidate is pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist that is currently undergoing clinical trials.
What sector is ALTIMMUNE INC (ALT) in?
ALTIMMUNE INC (ALT) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ALTIMMUNE INC's (ALT) competitors?
Notable peers of ALTIMMUNE INC (ALT) include Madrigal Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, 89bio and Eli Lilly. This peer set is informational only — not financial advice.
Is ALTIMMUNE INC (ALT) overbought or oversold right now?
ALTIMMUNE INC (ALT) is currently in oversold territory (its 14-day RSI is 27, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.